Acorda Therapeutics Inc EBITDA
Was ist das EBITDA von Acorda Therapeutics Inc?
EBITDA von Acorda Therapeutics Inc ist -$4.08
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acorda Therapeutics Inc
Was macht Acorda Therapeutics Inc?
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Unternehmen mit ebitda ähnlich Acorda Therapeutics Inc
- West High Yield (W.H.Y.) Resources hat EBITDA von -CAD$4.09
- Proactis Plc hat EBITDA von -£4.09
- CareTeQ hat EBITDA von -AUD$4.09
- General Moly hat EBITDA von -$4.09
- General Moly hat EBITDA von -$4.09
- General Moly hat EBITDA von -$4.09
- Acorda Therapeutics Inc hat EBITDA von -$4.08
- Ahsay Backup Software Development hat EBITDA von -HKD$4.08
- Manganese X hat EBITDA von -CAD$4.08
- Manganese X Corp hat EBITDA von -CAD$4.08
- Mega Uranium hat EBITDA von -CAD$4.08
- Krakatoa Resources hat EBITDA von -AUD$4.07
- Triumph Gold hat EBITDA von -CAD$4.07